India’s third homegrown vaccine, Biological E Ltd company’s vaccine Corbevax has received emergency use approval in India for use in children aged 12 to 18 years, announced the company recently. The company further said that the approval was received after Keenly observing the results of the ongoing phase 2 and phase 3 clinical trials. The Drugs Controller General of India has already approved the use of Corbevax among adults on December 28 last year.
According to government figures, as of now, more than 76 million children between the age of 15 and 17 have been inoculated mainly using Covaxin. After getting approval from India’s drug regulator, the company Managing Director Mahima Datula said,” We are pleased with this significant development that will help spread the vaccine in our country to people between the ages of 12 and 18.”
As per the announcement, the government ordered the purchase of around 5 crore doses of Corbevax and it is likely to be available in the market by February end this year. The government has also purchased the vaccine at a price of ₹145 per dose before taxes. It was in September last year, that the company Biological Erecived its approval to conduct the clinical trials of phase 2 and phase 3 of it.
In December, the vaccine got its approval to have emergency use in adults, and following this, the drug controller has given emergency use in children also. Last August, the Centre had earlier placed an order for 30 crore Corbevax doses. The vaccine is India’s third indigenous vaccine developed RBD protein sub-unit vaccine against Covid-19, made by Hyderabad-based firm Biological-E.
Meanwhile, India has now approved eight vaccines against covid, of which three vaccines– Covaxin, zyCoV-D, and Corbevax– have been approved for use in children. Of these, Covishield by Serum Institute of India and Covaxin by Bharat Biotech is being used in the national immunization program.